Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding

JCI Insight

Volumn 1, Issue 14, 2016, Pages

  Granoff, Dan M ^a   Giuntini, Serena ^a   Gowans, Flor A ^a   Lujan, Eduardo ^a   Sharkey, Kelsey ^a   Beernink, Peter T ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008939963     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.88907     Document Type: Article

References (57)

1. Meri S, Jördens M, Jarva H. Microbial complement inhibitors as vaccines. Vaccine. 2008;26 Suppl 8:I113–I117.
2. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176.
3. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease Control (CDC). Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–612.
4. Masignani V, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789–799.
5. Fletcher LD, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–2100.
6. Madico G, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501–510.
7. Schneider MC, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176(12):7566–7575.
8. Welsch JA, Ram S. Factor H and neisserial pathogenesis. Vaccine. 2008;26 Suppl 8:I40–I45.
9. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77(2):764–769.
10. Konar M, Beernink PT, Granoff DM. A Newly-Identified Polymorphism in Rhesus Macaque Complement Factor H Modulates Binding Affinity for Meningococcal FHbp. PLoS One. 2015;10(8):e0135996.
11. Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM. Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol. 2014;21(11):1505–1511.
12. Beernink PT, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011;186(6):3606–3614.
13. Granoff DM, Ram S, Beernink PT. Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?. Clin Vaccine Immunol. 2013;20(8):1099–1107.
14. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 2012;8(5):e1002688.
15. Costa I, Pajon R, Granoff DM. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio. 2014;5(5):e01625–e01614.
16. Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine. J Infect Dis. 2015;212(5):784–792.
17. Giuntini S, Beernink PT, Granoff DM. Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine. Vaccine. 2015;33(51):7168–7175.
18. Rossi R, Granoff DM, Beernink PT. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine. 2013;31(46):5451–5457.
19. Konar M, Rossi R, Walter H, Pajon R, Beernink PT. A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens. PLoS One. 2015;10(6):e0128185.
20. Snape MD, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71–e79.
21. Findlow J, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–1137.
22. Richmond PC, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30(43):6163–6174.
23. Marshall HS, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31(10):1061–1068.
24. Rossi R, Beernink PT, Giuntini S, Granoff DM. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine. Clin Vaccine Immunol. 2015;22(12):1227–1234.
25. Basta NE, et al. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. N Engl J Med. 2016;375(3):220–228.
26. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol. 2009;46(8-9):1647–1653.
27. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol. 2004;172(9):5606–5615.
28. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun. 2008;76(9):4232–4240.
29. Hale SF, Camaione L, Lomaestro BM. MenHibrix: a new combination meningococcal vaccine for infants and toddlers. Ann Pharmacother. 2014;48(3):404–411.
30. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis. 2011;5(9):e1302.
31. Law DK, et al. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets. BMC Microbiol. 2015;15:143.
32. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol. 2016;33(7):1870–1874.
33. Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis. 2013;208(4):627–636.
34. Beernink PT, Giuntini S, Costa I, Lucas AH, Granoff DM. Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein. MBio. 2015;6(3):e00842.
35. Ingram G, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(Pt 6):1602–1611.
36. Hakobyan S, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(5):1983–1990.
37. Martin M, et al. Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. Cell Death Differ. 2016;23(5):903–911.
38. Giuntini S, Granoff DM, Beernink PT, Ihle O, Bratlie D, Michaelsen TE. Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity. Clin Vaccine Immunol. 2016;23(8):698–706.
39. Giuntini S, Reason DC, Granoff DM. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun. 2012;80(1):187–194.
40. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology. 2004;111(1):66–74.
41. Rubin RL, Tang FL, Lucas AH, Spiegelberg HL, Tan EM. IgG subclasses of anti-tetanus toxoid antibodies in adult and newborn normal subjects and in patients with systemic lupus erythematosus, Sjogren’s syndrome, and drug-induced autoimmunity. J Immunol. 1986;137(8):2522–2527.
42. Naess LM, Rosenqvist E, Høiby EA, Michaelsen TE. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods. 1996;196(1):41–49.
43. Snape MD, et al. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. Pediatr Infect Dis J. 2016;35(4):e113–e123.
44. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A. 1988;85(5):1657–1661.
45. Fischetti VA, Horstmann RD, Pancholi V. Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun. 1995;63(1):149–153.
46. Melin M, et al. Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun. 2010;78(5):2089–2098.
47. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Björck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol. 2002;168(4):1886–1894.
48. Hovis KM, Tran E, Sundy CM, Buckles E, McDowell JV, Marconi RT. Selective binding of Borrelia burgdorferi OspE paralogs to factor H and serum proteins from diverse animals: possible expansion of the role of OspE in Lyme disease pathogenesis. Infect Immun. 2006;74(3):1967–1972.
49. Hellwage J, et al. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J Biol Chem. 2001;276(11):8427–8435.
50. Lujan E, Pajon R, Granoff DM. Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Infect Immun. 2016;84(2):452–458.
51. Frandoloso R, et al. Nonbinding site-directed mutants of transferrin binding protein B exhibit enhanced immunogenicity and protective capabilities. Infect Immun. 2015;83(3):1030–1038.
52. Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol. 2010;17(7):1074–1078.
53. Bovre K, et al. Neisseria meningitidis infections in Northern Norway: an epidemic in 1974-1975 due mainly to group B organisms. J Infect Dis. 1977;135(4):669–672.
54. Pajon R, Lujan E, Granoff DM. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine. 2016;34(5):643–649.
55. Mandrell RE, et al. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol. 1991;173(9):2823–2832.
56. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011. http://www.ncbi.nlm.nih.gov/books/NBK54050.
57. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology (Reading, Engl). 2009;155(Pt 9):2873–2883.